Preclinical Screening for Immunogenicity
PreDeFT is a concise report describing the potential immunogenicity of a protein or peptide sequence(s). In a PreDeFT report, EpiVax ranks your protein or peptide sequence(s) against other known immunogenic and non immunogenic proteins. The PreDeFT analysis also identifies specific regions contained within your protein or peptide sequence (referred to as epitope clusters) that have the potential to trigger an immune response. Unintended immune responses are a primary concern of the FDA in reviewing submissions for biologic IND’s. EpiVax’s PreDeFT analysis can be used to support your IND filing, therefore increasing the likelihood of a favorable review. Should the client wish to go beyond in silico screening, the in silico analysis can be validated in vitro and in vivo (using our proprietary HLA binding assays and HLA transgenic mice).
